NASDAQ:AXDX - Accelerate Diagnostics Stock Price, Price Target & More

$23.25 -0.10 (-0.43 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$23.35
Today's Range$23.13 - $23.90
52-Week Range$16.75 - $30.45
Volume106,500 shs
Average Volume237,254 shs
Market Capitalization$1.36 billion
P/E Ratio-20.04
Dividend YieldN/A
Beta2.13

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Debt-to-Equity RatioN/A
Current Ratio17.77%
Quick Ratio16.58%

Price-To-Earnings

Trailing P/E Ratio-20.04
Forward P/E Ratio-19.38
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.18 million
Price / Sales310.32
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book10.86

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-64,020,000.00
Net Margins-1,520.99%
Return on Equity-54.66%
Return on Assets-51.90%

Miscellaneous

EmployeesN/A
Outstanding Shares55,790,000

How to Become a New Pot Stock Millionaire

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its earnings results on Thursday, February, 15th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.06. The medical research company had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative net margin of 1,520.99% and a negative return on equity of 54.66%. View Accelerate Diagnostics' Earnings History.

What price target have analysts set for AXDX?

2 analysts have issued 12-month price objectives for Accelerate Diagnostics' stock. Their predictions range from $32.00 to $34.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $33.00 in the next twelve months. View Analyst Ratings for Accelerate Diagnostics.

What are Wall Street analysts saying about Accelerate Diagnostics stock?

Here are some recent quotes from research analysts about Accelerate Diagnostics stock:
  • 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (2/21/2018)
  • 2. BTIG Research analysts commented, "Outlook Remains The Same As the company preannounced Q4 revenue and provided FY18 revenue expectations on January 10th , the company’s formal earnings call was fairly straightforward without surprises. The messaging was largely consistent with what we learned from the company’s JPM conference presentation though we now may expect an update on progress with the FDA on the LRTI test as early as the Q1 call. Overall, we remain very positive on the technology and the total opportunity but feel the company needs to consistently hit estimates through the course of the year for the Street to regain comfort with the model. We maintain our Neutral rating.   Modestly tweaking our estimates for gross margin. Our revenue estimates are unchanged but we have increased our gross margin estimates to reflect better trends in Q4. Our full year FY18 revenue estimate is $25M and we assume roughly 2/3 of revenue will be recognized in the 2H. For Q1, we model a slight uptick sequentially from Q4 revenue of $2.12M to $3.2M; of note, this estimate also seems to be lower than other estimates on the Street of $4-5M. Given the timing of hospital purchasing, we prefer to have a conservative bias in the start of the year.   Valuation: Shares are Neutral rated based on our DCF analysis. Risks follow." (2/18/2018)

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:
  • Mr. Lawrence Mehren, Chief Exec. Officer, Pres and Director (Age 52)
  • Mr. Steve Reichling, Chief Financial Officer, Chief Accounting Officer and Sec. (Age 40)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries Ph.D., D(ABMM), M (ASCP)CM, Chief Scientific Officer
  • Mr. Steven W. Metzger, Head of Discovery & New Products (Age 44)

Has Accelerate Diagnostics been receiving favorable news coverage?

Media headlines about AXDX stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the medical research company an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $23.25.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $1.36 billion and generates $4.18 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (AXDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Accelerate Diagnostics (NASDAQ:AXDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Accelerate Diagnostics in the last 12 months. Their average twelve-month price target is $33.00, suggesting that the stock has a possible upside of 41.94%. The high price target for AXDX is $34.00 and the low price target for AXDX is $32.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.503.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.00$33.00$33.00$33.00
Price Target Upside: 41.94% upside31.21% upside10.00% upside17.65% upside

Accelerate Diagnostics (NASDAQ:AXDX) Consensus Price Target History

Price Target History for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ:AXDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
6/5/2017Piper JaffrayReiterated RatingOverweight$30.00 -> $32.00LowView Rating Details
8/9/2016JPMorgan ChaseBoost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Accelerate Diagnostics (NASDAQ:AXDX) Earnings History and Estimates Chart

Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ:AXDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.2 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS

Accelerate Diagnostics (NASDAQ AXDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018Q4 2017($0.3250)($0.27)$2.10 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.32)($0.31)$2.78 million$0.83 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.3070)$1.40 million$0.70 millionViewListenView Earnings Details
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.32)($0.35)$0.02 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.26)($0.29)$0.04 million$0.16 millionViewN/AView Earnings Details
3/9/2016Q4 2015($0.29)$0.02 millionViewN/AView Earnings Details
11/2/2015Q3 2015($0.25)$0.09 millionViewN/AView Earnings Details
7/31/2015Q2 2015($0.27)$0.02 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.20)$0.01 millionViewN/AView Earnings Details
2/26/2015Q4 2014($0.20)$0.08 millionViewN/AView Earnings Details
11/4/2014Q3 2014($0.20)$0.02 millionViewN/AView Earnings Details
8/1/2014Q2 2014($0.19)$0.01 millionViewN/AView Earnings Details
5/2/2014Q1 2014($0.12)$0.01 millionViewN/AView Earnings Details
3/7/2014Q4 2013($0.13)$0.01 millionViewN/AView Earnings Details
11/8/2013Q3 2013($0.10)$0.01 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.13)$0.01 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.09)$0.02 millionViewN/AView Earnings Details
12/14/2012Q4 2012($0.06)ViewN/AView Earnings Details
10/26/2012Q3 2012($0.33)ViewN/AView Earnings Details
6/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
3/15/2012Q1 2012($0.03)ViewN/AView Earnings Details
12/14/2011Q4 2011($0.04)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.03)ViewN/AView Earnings Details
9/17/2010Q3 2010$0.17ViewN/AView Earnings Details
6/16/2008Q2 2008($0.04)ViewN/AView Earnings Details
3/17/2008Q1 2008($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Accelerate Diagnostics (NASDAQ:AXDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Accelerate Diagnostics (NASDAQ AXDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 50.00%
Institutional Ownership Percentage: 44.89%
Insider Trading History for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ AXDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2018Jack W SchulerDirectorBuy100$25.00$2,500.00View SEC Filing  
3/1/2018Jack W SchulerDirectorBuy15,000$25.15$377,250.00View SEC Filing  
2/22/2018Jack W SchulerDirectorBuy10,000$25.21$252,100.00View SEC Filing  
2/20/2018Jack W SchulerDirectorBuy20,000$24.95$499,000.00View SEC Filing  
11/17/2017Jack W SchulerDirectorBuy5,500$22.00$121,000.00View SEC Filing  
11/15/2017Jack W SchulerDirectorBuy20,000$20.00$400,000.00View SEC Filing  
11/13/2017Jack W SchulerDirectorBuy20,000$18.98$379,600.00View SEC Filing  
11/10/2017Jack W SchulerDirectorBuy51,181$18.67$955,549.27View SEC Filing  
11/8/2017Jack W SchulerDirectorBuy50,000$18.46$923,000.00View SEC Filing  
11/6/2017Jack W SchulerDirectorBuy340,964$18.51$6,311,243.6444,670View SEC Filing  
10/18/2017Jack W SchulerDirectorBuy45,000$20.14$906,300.00View SEC Filing  
10/16/2017Jack W SchulerDirectorBuy59,922$20.07$1,202,634.54View SEC Filing  
10/13/2017Jack W SchulerDirectorBuy61,300$19.29$1,182,477.00View SEC Filing  
10/12/2017Jack W SchulerDirectorBuy276,200$19.74$5,452,188.00View SEC Filing  
10/11/2017Jack W SchulerDirectorBuy51,600$20.27$1,045,932.00View SEC Filing  
8/21/2017Jack W SchulerDirectorBuy50,000$21.45$1,072,500.00View SEC Filing  
8/17/2017Lawrence MehrenInsiderSell223,215$22.40$5,000,016.00762,381View SEC Filing  
8/15/2017Jack W SchulerDirectorBuy8,200$21.35$175,070.00View SEC Filing  
8/14/2017Jack W SchulerDirectorBuy23,400$21.35$499,590.00View SEC Filing  
8/11/2017Jack W SchulerDirectorBuy80,000$21.43$1,714,400.00View SEC Filing  
6/21/2017Steven ReichlingInsiderSell30,000$28.90$867,000.0030,700View SEC Filing  
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.002,045,560View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00173,079View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.009,800View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Accelerate Diagnostics (NASDAQ AXDX) News Headlines

Source:
DateHeadline
Accelerate Diagnostics (AXDX) Upgraded at BidaskClubAccelerate Diagnostics (AXDX) Upgraded at BidaskClub
www.americanbankingnews.com - April 25 at 12:58 AM
Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018
finance.yahoo.com - April 21 at 9:11 AM
 Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) Will Announce Quarterly Sales of $2.79 Million Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) Will Announce Quarterly Sales of $2.79 Million
www.americanbankingnews.com - April 21 at 4:32 AM
Head-To-Head Comparison: Precipio (PRPO) vs. Accelerate Diagnostics (AXDX)Head-To-Head Comparison: Precipio (PRPO) vs. Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - April 20 at 7:18 PM
Zacks: Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) to Post -$0.31 Earnings Per ShareZacks: Brokerages Anticipate Accelerate Diagnostics, Inc. (AXDX) to Post -$0.31 Earnings Per Share
www.americanbankingnews.com - April 19 at 9:51 AM
BTIG Research Reaffirms Buy Rating for Accelerate Diagnostics (AXDX)BTIG Research Reaffirms Buy Rating for Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - April 18 at 8:34 PM
BidaskClub Downgrades Accelerate Diagnostics (AXDX) to HoldBidaskClub Downgrades Accelerate Diagnostics (AXDX) to Hold
www.americanbankingnews.com - April 16 at 12:03 PM
Accelerate Diagnostics (AXDX) Lowered to Sell at BidaskClubAccelerate Diagnostics (AXDX) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 10:42 PM
Accelerate Diagnostics (AXDX) Downgraded by ValuEngine to SellAccelerate Diagnostics (AXDX) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 7:51 PM
 Brokerages Expect Accelerate Diagnostics, Inc. (AXDX) Will Post Quarterly Sales of $2.62 Million Brokerages Expect Accelerate Diagnostics, Inc. (AXDX) Will Post Quarterly Sales of $2.62 Million
www.americanbankingnews.com - April 4 at 4:00 AM
 Analysts Anticipate Accelerate Diagnostics, Inc. (AXDX) to Announce -$0.31 Earnings Per Share Analysts Anticipate Accelerate Diagnostics, Inc. (AXDX) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - April 2 at 9:12 AM
 Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX) Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - April 1 at 1:26 AM
Accelerate Diagnostics (AXDX) Stock Rating Lowered by BidaskClubAccelerate Diagnostics (AXDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 11:21 AM
Accelerate Diagnostics (AXDX) Stock Rating Upgraded by ValuEngineAccelerate Diagnostics (AXDX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 8:44 PM
Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering - GlobeNewswire (press release)Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering - GlobeNewswire (press release)
globenewswire.com - March 23 at 4:33 PM
Accelerate Diagnostics (AXDX) Prices of $150 Million Convertible Notes OfferingAccelerate Diagnostics (AXDX) Prices of $150 Million Convertible Notes Offering
www.streetinsider.com - March 23 at 9:19 AM
Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes OfferingAccelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering
finance.yahoo.com - March 23 at 9:19 AM
Accelerate Diagnostics Inc. Announces $150 Million Convertible ... - GlobeNewswire (press release)Accelerate Diagnostics Inc. Announces $150 Million Convertible ... - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:32 PM
Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes OfferingAccelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering
finance.yahoo.com - March 22 at 9:34 AM
Brokerages Expect Accelerate Diagnostics Inc (AXDX) to Post ($0.31) EPSBrokerages Expect Accelerate Diagnostics Inc (AXDX) to Post ($0.31) EPS
www.americanbankingnews.com - March 13 at 5:30 PM
Head to Head Analysis: Luna Innovations (LUNA) and Accelerate Diagnostics (AXDX)Head to Head Analysis: Luna Innovations (LUNA) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - March 9 at 9:09 AM
Accelerate Diagnostics Inc (AXDX) Director Purchases $377,250.00 in StockAccelerate Diagnostics Inc (AXDX) Director Purchases $377,250.00 in Stock
www.americanbankingnews.com - March 5 at 7:00 PM
Lombard Odier Asset Management USA Corp Has $3.41 Million Holdings in Accelerate Diagnostics Inc (AXDX)Lombard Odier Asset Management USA Corp Has $3.41 Million Holdings in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 3 at 4:42 PM
Next Century Growth Investors LLC Raises Holdings in Accelerate Diagnostics Inc (AXDX)Next Century Growth Investors LLC Raises Holdings in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 2 at 5:58 PM
Accelerate Diagnostics Inc (AXDX) Files 10-K for the Fiscal Year Ended on December 31, 2017Accelerate Diagnostics Inc (AXDX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 9:04 AM
Baird Financial Group Inc. Purchases New Position in Accelerate Diagnostics Inc (AXDX)Baird Financial Group Inc. Purchases New Position in Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - March 1 at 4:50 AM
Accelerate Diagnostics Inc (AXDX) Director Purchases $252,100.00 in StockAccelerate Diagnostics Inc (AXDX) Director Purchases $252,100.00 in Stock
www.americanbankingnews.com - February 26 at 3:28 PM
Jack W. Schuler Purchases 20,000 Shares of Accelerate Diagnostics Inc (AXDX) StockJack W. Schuler Purchases 20,000 Shares of Accelerate Diagnostics Inc (AXDX) Stock
www.americanbankingnews.com - February 22 at 6:32 PM
Accelerate Diagnostics (AXDX) Upgraded to "Hold" at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 21 at 6:04 PM
BTIG Research Reaffirms "Hold" Rating for Accelerate Diagnostics (AXDX)BTIG Research Reaffirms "Hold" Rating for Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 18 at 3:09 PM
Notable Friday Option Activity: AXDX, NSM, ELFNotable Friday Option Activity: AXDX, NSM, ELF
www.nasdaq.com - February 16 at 4:41 PM
Accelerate Diagnostics (AXDX) Announces Quarterly  Earnings ResultsAccelerate Diagnostics (AXDX) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 16 at 10:56 AM
Accelerate Diagnostics reports 4Q lossAccelerate Diagnostics reports 4Q loss
www.cnbc.com - February 16 at 9:03 AM
Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
finance.yahoo.com - February 15 at 4:40 PM
Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 14 at 9:10 PM
Accelerate Diagnostics Sees Unusually Large Options Volume (AXDX)Accelerate Diagnostics Sees Unusually Large Options Volume (AXDX)
www.americanbankingnews.com - February 11 at 1:52 AM
-$0.33 Earnings Per Share Expected for Accelerate Diagnostics Inc (AXDX) This Quarter-$0.33 Earnings Per Share Expected for Accelerate Diagnostics Inc (AXDX) This Quarter
www.americanbankingnews.com - February 10 at 3:12 PM
Accelerate Diagnostics (AXDX) Cut to "Sell" at ValuEngineAccelerate Diagnostics (AXDX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - February 9 at 11:46 PM
Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018
finance.yahoo.com - February 9 at 9:17 AM
Critical Contrast: Sirona Dental Systems (SIRO) and Accelerate Diagnostics (AXDX)Critical Contrast: Sirona Dental Systems (SIRO) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 8 at 1:18 AM
 Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 7 at 11:56 AM
Notable Friday Option Activity: AXDX, MSTR, LAYNNotable Friday Option Activity: AXDX, MSTR, LAYN
www.nasdaq.com - January 27 at 9:38 AM
Accelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.33 Per ShareAccelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - January 24 at 3:26 PM
Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)
www.americanbankingnews.com - January 21 at 5:26 AM
Accelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Accelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per ShareAccelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per Share
www.americanbankingnews.com - January 15 at 3:02 AM
Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial SurveyAccelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey
www.americanbankingnews.com - January 13 at 3:32 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:30 PM
Accelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia AssayAccelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia Assay
www.streetinsider.com - January 11 at 9:24 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
finance.yahoo.com - January 10 at 10:50 AM

SEC Filings

Accelerate Diagnostics (NASDAQ:AXDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Accelerate Diagnostics (NASDAQ:AXDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Accelerate Diagnostics (NASDAQ AXDX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.